FDA secures new pay deal for civil servants
This package includes:
- An addendum to the 2023/24 Pay Remit Guidance to enable employers to pay an additional fixed £1,500 non-consolidated payment to assist with the increased cost of living. This will be paid to all civil servants covered by the pay remit process, including those on the centralised fast stream and will be subject to pro-rata arrangements for part time staff.
- A commitment that the introduction of capability-based pay for the SCS is a ministerial priority and that the Cabinet Office will undergo a period of work as a matter of priority. The minister has committed to intensive engagement with the FDA on this issue and agreed meet with us as part of his personal commitment to its implementation.
- A commitment to make no changes to the Civil Service Compensation Scheme before 2025. Alongside a commitment to avoid compulsory redundancies across the civil service.
You can read the full details of the proposed package on the gov.uk website.
FDA General Secretary Dave Penman has welcomed this new pay deal: “The threat of industrial action must always be a last resort and the FDA’s decision to ballot for national industrial action over pay for the first time in 40 years was not taken lightly. It was intended to send a clear message to the government that enough was enough as they had failed to demonstrate that they valued the civil service equally with the rest of the public sector.
Related News
-
9% pay rise for NI civil servants ‘genuine attempt to tackle pay erosion’, says FDA
The FDA is recommending to members to accept the Northern Ireland civil service pay offer for 2024/25, which represents a 9% increase over a 20-month period.
-
FDA calls for widespread reform across the civil service in New Year message to government
The FDA has shared its annual New Year message to the government, in which FDA Assistant General Secretary Lauren Crowley outlines the need for significant reform across the civil service.
-
Driving improvement
If the government wants efficiencies, it needs to address the big challenge of civil service pay reform, writes FDA General Secretary Dave Penman.